Medscape

Genetic Liver Disease

A number of presentations held during the 54th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) addressed important advances in genetic/metabolic liver disease. A ...
Business Wire

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI® (maralixibat) oral solution in ...
Business Wire

LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021

The analysis examined 22 patients with BSEP deficiency, or PFIC2, following treatment with LIVMARLI as part of the INDIGO study. The dose-escalation study evaluated LIVMARLI at 266 µg/kg per day ...
Healio

Maralixibat improves pruritis, reduces total serum bile acids in all PFIC subtypes

Please provide your email address to receive an email when new articles are posted on . Treatment with maralixibat led to greater reductions in least-squares mean change from baseline in morning ...